SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Medeor Therapeutics, Inc., a clinical-stage company dedicated to the development and commercialization of immunotherapies for transplantation, today announced the appointment of Daniel Brennan, MD, as Chief Medical Officer. In his role, Dr. Brennan will oversee the clinical development program for Medeor’s cellular therapy platform aimed at minimizing and eliminating the need for immunosuppressive therapy for preventing transplant rejection.
“A world-renowned scientific leader, Dan’s lifelong work has greatly advanced the transplantation field. His addition to the management team at Medeor will provide critical support in advancing our clinical programs at this pivotal time,” said Giovanni Ferrara, President and CEO of Medeor Therapeutics. “His clinical vision and leadership coupled with his unparalleled medical and research experience will be instrumental as we work toward our goal of making long-lasting immune tolerance a reality.”
“Medeor Therapeutics is setting a new path in helping organ transplant patients lead a life without being tethered to a daily regimen of immunosuppressants and the potential life-threatening side effects that come with them,” said Dr. Brennan. “This technology can bring a much-needed improvement to the transplantation field and I look forward to working with the management team to bring it through Phase 3 clinical trials and commercialization.”
Dr. Brennan currently also serves as the inaugural Medical Director at the Comprehensive Transplant Center at Johns Hopkins Hospital and Professor of Nephrology at the Johns Hopkins Division of Renal Medicine. Prior to joining Johns Hopkins, Dr. Brennan was the Alan A. and Edith L. Wolff Professor of Renal Diseases at Washington University and the Director of Transplant Nephrology at the Washington University School of Medicine. He has written more than 300 original publications and several textbook chapters in the areas of viral infections, induction immunosuppression therapy, pharmacoeconomics and outcomes research in transplantation and islet transplantation.
About Medeor Therapeutics, Inc.
Medeor Therapeutics is working to improve the lives of transplant patients by eliminating or reducing the need for a life-long regimen of immunosuppressant medications and their potential life-threatening side effects. Medeor’s Phase 3 clinical study is demonstrating the significant opportunities of this one-time therapy. For more information, visit www.medeortx.com.
